ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Politics, Short Tempers, Grievances Dominate NIH Panel On Unconventional Medical Practices

September 25, 1992

Study Finds Short Term Tests Predict Carcinogenicity

April 25, 1980

Arzerra Promising For Heavily Pre-Treated CLL Patients

December 26, 2008

Chemical Carcinogenesis

November 18, 1994

NCI Intramural Budget: Well-Funded Labs, High Costs, Or Deceiving Appearances?

April 21, 1995

AACR, ASCO Publish Reports Examining U.S. Cancer Care

April 4, 2014